HomeCompanyTechnologyProduct CandidatesPartneringNewsContact

welcome to Kenta Biotech and the leading product KBPA101
  » imprint    

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Our mission:
develop fully human monoclonal antibodies
for the adjunctive treatment of severe hospital acquired infections

We are a biotech company focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting.

The MabIgX® technology for the generation and selection of fully human monoclonal antibodies (mAbs) allows the harnessing of the power of the human immune system and transforms it into highly effective therapeutic antibodies for the treatment of life threatening infections. The unique technology in combination with focused scientific and clinical expertise had enabled Kenta Biotech to rapidly move innovative antibody therapies from bench to high medical need patients.

Kenta Biotech AG
Löberenstrasse 47
CH-6301 Zug